🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Prospective Study of Antiplatelet and Anticoagulation Therapy in Hereditary Haemorrhagic Telangiectasia

RecruitingNAAges 18 Years - anyAllUniversity Hospital, Clermont-Ferrand
NCT05641142 on ClinicalTrials.gov ↗
💬

In plain words

What the trial is, and whether it could suit you

The goal of this clinical trial is to evaluate in real life, in patients with Hereditary Hemorrhagic Telangiectasia (HHT), the tolerance of the strategy of use of anticoagulant and/or antiplatelet, by comparing a new exposure period (first trimester of treatment) to a period of reference non-exposure (last trimester before start of treatment).

Sign in to get the eligibility rules as simple questions to take to your doctor.

Sign in
📋 Eligibility rules (as published)
Inclusion Criteria: * Patient with Rendu-Osler disease with an indication of antiplatelet and/or anticoagulant introduced for less than 3 months (inclusion period within 3 months of exposure) * Age \> 18 years old * Patient able to understand and agree to participate in the study * Affiliation to a social security system Exclusion Criteria: * Patient with an indication of antiplatelet and/or anticoagulant but for whom treatment has not been introduced or introduced for more than 3 months * Refusal to participate * Pregnant woman or who are breast feeding * Patients under maintenance of justice, wardship or legal guardianship
💊

What it tests

  • monitoring the use of anticoagulant and/or antiplatelet therapy in patients with osler rendering disease
📍

Where

18 sites
CHU d'Angers
Angers, France
CHU de Bordeaux
Bordeaux, France
Hôpital Ambroise Paré
Boulogne-Billancourt, France
CHU de Caen Normandie
Caen, France
CHU clermont-ferrand
Clermont-Ferrand, France
CHU de Dijon
Dijon, France
CHRU de Lille
Lille, France
Hospices Civiles de Lyon
Lyon, France

…and 10 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy